


WHAT IS CLAIMED IS:

- 1 1. Crystalline Form I of a compound of Formula (I):



- 2
3 characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at
4 11.1, 11.6, 13.8, 14.7, 15.4, 16.6, 17.0, 18.6, 19.3, 20.1, 21.3, 22.1, 23.0, 24.8, 26.6, 27.3, and
5 29.1 degrees 2θ (± 0.2 degrees 2θ).

- 1 2. The crystalline Form I of claim 1, characterized by an XRPD pattern
2 comprising five or more peaks at 11.1, 11.6, 13.8, 14.7, 15.4, 16.6, 17.0, 18.6, 19.3, 20.1, 21.3,
3 22.1, 23.0, 24.8, 26.6, 27.3, and 29.1 degrees 2θ (± 0.2 degrees 2θ).

- 1 3. The crystalline Form I of claim 1, characterized by an XRPD pattern
2 comprising seven or more peaks at 11.1, 11.6, 13.8, 14.78, 15.4, 16.6, 17.0, 18.6, 19.3, 20.1,
3 21.3, 22.1, 23.0, 24.8, 26.6, 27.3, and 29.1 degrees 2θ (± 0.2 degrees 2θ).

- 1 4. The crystalline Form I of claim 1, characterized by an XRPD pattern
2 comprising peaks at 11.1, 13.8, 18.6, 20.1, 23.0, and 24.8 degrees 2θ (± 0.2 degrees 2θ).

- 1 5. The crystalline Form I of claim 4, wherein the XRPD pattern further
2 comprises one or more peaks at 11.6, 14.7, 15.4, 16.6, 17.0, 19.3, 21.3, 22.1, 24.8, 26.6, 27.3,
3 and 29.1 degrees 2θ (± 0.2 degrees 2θ).

- 1 6. The crystalline Form I of claim 4, wherein the XRPD pattern further
2 comprises three or more peaks at 11.6, 14.7, 15.4, 16.6, 17.0, 19.3, 21.3, 22.1, 24.8, 26.6, 27.3,
3 and 29.1 degrees 2θ (± 0.2 degrees 2θ).

1 7. The crystalline Form I of claim 4, wherein the XRPD pattern further
2 comprises five or more peaks at 11.6, 14.7, 15.4, 16.6, 17.0, 19.3, 21.3, 22.1, 24.8, 26.6, 27.3,
3 and 29.1 degrees 2θ (± 0.2 degrees 2θ).

1 8. The crystalline Form I of claim 1, the X-ray powder diffraction pattern is
2 substantially in accordance with FIG. 1.


1 9. The crystalline Form I of claim 1, which is substantially free of other
2 crystalline or amorphous forms of a compound of Formula (I).

1 10. The crystalline Form I of any one of claims 1 to 9, further characterized by
2 a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about
3 163.9°C.

1 11. The crystalline Form I of any one of claims 1 to 9, further characterized by
2 a melting point onset of about 155.1°C as determined by a differential scanning calorimetry
3 thermogram (DSC).

1 12. The crystalline Form I of claim 10 or 11, wherein the DSC thermogram is
2 substantially in accordance with FIG. 2.

1 13. Crystalline Form II of a compound of Formula (I):



2
3 characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at
4 10.1, 10.8, 12.8, 13.7, 16.5, 17.7, 19.0, 22.8, and 24.6 degrees 2θ (± 0.2 degrees 2θ).

1 **14.** The crystalline Form II of claim **13**, characterized by an XRPD pattern
2 comprising five or more peaks at 10.1, 10.8, 12.8, 13.7, 16.5, 17.7, 19.0, 22.8, and 24.6 degrees
3 2 θ ($\pm$ 0.2 degrees 2 θ).

1 **15.** The crystalline Form II of claim **13**, characterized by an XRPD pattern
2 comprising seven or more peaks at 10.1, 10.8, 12.8, 13.7, 16.5, 17.7, 19.0, 22.8, and 24.6 degrees
3 2 θ ($\pm$ 0.2 degrees 2 θ).

1 **16.** The crystalline Form II of claim **13**, characterized by an XRPD pattern
2 comprising peaks at 16.5, 22.8, and 24.6 degrees 2 θ ($\pm$ 0.2 degrees 2 θ).

1 **17.** The crystalline Form II of claim **16**, wherein the XRPD pattern further
2 comprises one or more peaks at 10.1, 10.8, 12.8, 13.7, 17.7, and 19.0 degrees 2 θ ($\pm$ 0.2 degrees
3 2 θ).

1 **18.** The crystalline Form II of claim **16**, wherein the XRPD pattern further
2 comprises three or more peaks at 10.1, 10.8, 12.8, 13.7, 17.7, and 19.0 degrees 2 θ ($\pm$ 0.2 degrees
3 2 θ).

1 **19.** The crystalline Form II of claim **16**, wherein the XRPD pattern further
2 comprises five or more peaks at 10.1, 10.8, 12.8, 13.7, 17.7, and 19.0 degrees 2 θ ($\pm$ 0.2 degrees
3 2 θ).

1 **20.** The crystalline Form II of claim **13**, the X-ray powder diffraction pattern
2 is substantially in accordance with FIG. 3.


1 **21.** The crystalline Form II of claim **13**, which is substantially free of other
2 crystalline or amorphous forms of a compound of Formula (I).

1 **22.** The crystalline Form II of any one of claims **13** to **21**, further
2 characterized by a differential scanning calorimetry (DSC) thermogram comprising an
3 endothermic peak at about 166.5°C.

1 **23.** The crystalline Form II of any one of claims **13** to **22**, further
2 characterized by a melting point onset of about 157.4°C as determined by a differential scanning
3 calorimetry thermogram (DSC).

1 **24.** The crystalline Form II of claim **22** or **23**, wherein the DSC thermogram is
2 substantially in accordance with FIG. 4.

1 **25.** Crystalline Form III of a compound of Formula (I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 6.6, 10.9, 14.2, 16.1, 18.4, 19.3, 20.2, 22.0, 24.7, and 28.1 degrees 2θ (± 0.2 degrees 2θ).

1 **26.** The crystalline Form III of claim **25**, characterized by an XRPD pattern
2 comprising five or more peaks at 6.6, 10.9, 14.2, 16.1, 18.4, 19.3, 20.2, 22.0, 24.7, and 28.1
3 degrees 2θ (± 0.2 degrees 2θ).

1 **27.** The crystalline Form III of claim **25**, characterized by an XRPD pattern
2 comprising seven or more peaks at 6.6, 10.9, 14.2, 16.1, 18.4, 19.3, 20.2, 22.0, 24.7, and 28.1
3 degrees 2θ (± 0.2 degrees 2θ).

1 **28.** The crystalline Form III of claim **25**, characterized by an XRPD pattern
2 comprising peaks at 6.6, 10.9, 14.2, 16.1, 18.4, and 19.3 degrees 2 θ ($\pm$ 0.2 degrees 2 θ).

1 **29.** The crystalline Form III of claim **28**, wherein the XRPD pattern further
2 comprises one or more peaks at 20.2, 22.0, 24.7, and 28.1 degrees 2 θ ($\pm$ 0.2 degrees 2 θ).

1 **30.** The crystalline Form III of claim **28**, wherein the XRPD pattern further
2 comprises three or more peaks at 20.2, 22.0, 24.7, and 28.1 degrees 2 θ ($\pm$ 0.2 degrees 2 θ).

1 **31.** The crystalline Form III of claim **25**, the X-ray powder diffraction pattern
2 is substantially in accordance with FIG. 5.


1 **32.** The crystalline Form III of claim **25**, which is substantially free of other
2 crystalline or amorphous forms of a compound of Formula (I).

1 **33.** The crystalline Form III of any one of claims **25** to **32**, further
2 characterized by a differential scanning calorimetry (DSC) thermogram comprising an
3 endothermic peak at about 161.8°C.

1 **34.** The crystalline Form III of any one of claims **25** to **32**, further
2 characterized by a melting point onset of about 149.6°C as determined by a differential scanning
3 calorimetry thermogram (DSC).

1 **35.** The crystalline Form III of claim **33** or **34**, wherein the DSC thermogram
2 is substantially in accordance with FIG. 6.

1 **36.** Crystalline Form IV of a compound of Formula (I):



2
3 characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at
4 6.0, 11.2, 14.1, 17.0, 19.5, 23.2, 25.1, 27.1, and 28.9 degrees 2θ (± 0.2 degrees 2θ).

1 **37.** The crystalline Form IV of claim **36**, characterized by an XRPD pattern
2 comprising five or more peaks at 6.0, 11.2, 14.1, 17.0, 19.5, 23.2, 25.1, 27.1, and 28.9 degrees 2θ
3 (± 0.2 degrees 2θ).

1 **38.** The crystalline Form IV of claim **36**, characterized by an XRPD pattern
2 comprising seven or more peaks at 6.0, 11.2, 14.1, 17.0, 19.5, 23.2, 25.1, 27.1, and 28.9 degrees
3 2θ (± 0.2 degrees 2θ).

1 **39.** The crystalline Form IV of claim **36**, characterized by an XRPD pattern
2 comprising peaks at 14.1, 17.0, 19.5, 23.2, and 25.1 degrees 2θ (± 0.2 degrees 2θ).


1 **40.** The crystalline Form IV of claim **39**, wherein the XRPD pattern further
2 comprises one or more peaks at 6.0, 11.2, 27.1, and 28.9 degrees 2θ (± 0.2 degrees 2θ).

1 **41.** The crystalline Form IV of claim **39**, wherein the XRPD pattern further
2 comprises three or more peaks at 6.0, 11.2, 27.1, and 28.9 degrees 2θ (± 0.2 degrees 2θ).

1 **42.** The crystalline Form IV of claim **36**, the X-ray powder diffraction pattern
2 is substantially in accordance with FIG. 7.

1 **43.** The crystalline Form IV of claim **36**, which is substantially free of other
2 crystalline or amorphous forms of a compound of Formula (I).

1 **44.** Crystalline Form V of a compound of Formula (I):



2 characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at
3 10.4, 15.1, 15.8, 16.3, 16.8, 18.5, 19.1, 19.7, 21.7, 22.1, 23.0, 23.5, 26.0, 26.5, 28.4, 28.9, and
4 31.4 degrees 2θ (± 0.2 degrees 2θ).

1 **45.** The crystalline Form V of claim **44**, characterized by an XRPD pattern
2 comprising five or more peaks at 10.4, 15.1, 15.8, 16.3, 16.8, 18.5, 19.1, 19.7, 21.7, 22.1, 23.0,
3 23.5, 26.0, 26.5, 28.4, 28.9, and 31.4 degrees 2θ (± 0.2 degrees 2θ).

1 **46.** The crystalline Form V of claim **44**, characterized by an XRPD pattern
2 comprising seven or more peaks at 10.4, 15.1, 15.8, 16.3, 16.8, 18.5, 19.1, 19.7, 21.7, 22.1, 23.0,
3 23.5, 26.0, 26.5, 28.4, 28.9, and 31.4 degrees 2θ (± 0.2 degrees 2θ).

1 **47.** The crystalline Form V of claim **44**, characterized by an XRPD pattern
2 comprising peaks at 15.8, 16.3, 16.8, 18.5, 19.1, 21.7, 22.1, and 23.0 degrees 2θ (± 0.2 degrees
3 2θ).

1 **48.** The crystalline Form V of claim **47**, wherein the XRPD pattern further
2 comprises one or more peaks at 10.4, 15.1, 19.7, and 23.6 degrees 2θ (± 0.2 degrees 2θ).

1 **49.** The crystalline Form V of claim **47**, wherein the XRPD pattern further
2 comprises three or more peaks at 10.4, 15.1, 19.7, and 23.6 degrees 2θ (± 0.2 degrees 2θ).

1 **50.** The crystalline Form V of claim **44**, the X-ray powder diffraction pattern
2 is substantially in accordance with FIG. 8.


1 **51.** The crystalline Form V of any one of claims **44-50**, which is substantially
2 free of other crystalline or amorphous forms of a compound of Formula (I).

1 **52.** The crystalline Form V of any one of claims **44-51**, further characterized
2 by a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at
3 about 150.4°C.

1 **53.** The crystalline Form V of any one of claims **44-52**, further characterized
2 by a melting point onset of about 135.8°C as determined by a differential scanning calorimetry
3 thermogram (DSC).

1 **54.** The crystalline Form V of claim **52** or **53**, wherein the DSC thermogram is
2 substantially in accordance with FIG. 9.

1 **55.** Crystalline Form VI of a compound of Formula (I):



(I),

2
3 characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at
4 5.8, 10.4, 16.2, 19.4, 21.3, 22.4, 24.4, 27.5, and 31.1 degrees 2θ (± 0.2 degrees 2θ).

1 **56.** The crystalline Form VI of claim **55**, characterized by an XRPD pattern
2 comprising five or more peaks at 5.8, 10.4, 16.2, 19.4, 21.3, 22.4, 24.4, 27.5, and 31.1 degrees
3 2θ (± 0.2 degrees 2θ).

1 **57.** The crystalline Form VI of claim **55**, characterized by an XRPD pattern
2 comprising peaks at 19.4, 21.3, 22.4, and 24.4 degrees 2θ (± 0.2 degrees 2θ).

1 **58.** The crystalline Form VI of claim **57**, wherein the XRPD pattern further
2 comprises one or more peaks at 5.8, 10.4, 27.5 and 31.1 degrees 2θ (± 0.2 degrees 2θ).

1 **59.** The crystalline Form VI of claim **57**, wherein the XRPD pattern further
2 comprises three or more peaks at 5.8, 10.4, 27.5 and 31.1 degrees 2θ (± 0.2 degrees 2θ).

1 **60.** The crystalline Form VI of any one of claims **55-59**, wherein the X-ray
2 powder diffraction pattern is substantially in accordance with FIG. 10.

1 **61.** The crystalline Form VI of any one of claims **55-60**, which is substantially
2 free of other crystalline or amorphous forms of a compound of Formula (I).

1 **62.** The crystalline Form VI of any one of claims **55-61**, further characterized
2 by a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at
3 about 142.9°C.

1 **63.** The crystalline Form VI of any one of claims **55-62**, further characterized
2 by a melting point onset of about 116.6°C as determined by a differential scanning calorimetry
3 thermogram (DSC).

1 **64.** The crystalline Form VI of claim **62** or **63**, wherein the DSC thermogram
2 is substantially in accordance with FIG. 11.

1 **65.** A pharmaceutical composition comprising a crystalline form of any one of
2 claims **1** to **64**, and a pharmaceutically acceptable excipient.

1 **66.** A method of treating a disease, disorder, or condition, mediated at least in
2 part by CD73, said method comprising administering an effective amount of a crystalline form of
3 the compound of any one of claims **1** to **64**, to a subject in need thereof.

1 **67.** The method of claim **66**, wherein the compound is administered in an
2 amount effective to reverse, stop or slow the progression of CD73-mediated immunosuppression.

1 **68.** The method of claim **66**, wherein the disease, disorder, or condition is
2 cancer.

1 **69.** The method of claim **68**, wherein the cancer is a cancer of the prostate,
2 colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head,
3 neck, skin (including melanoma and basal carcinoma), mesothelial lining, white blood cell
4 (including lymphoma and leukemia), esophagus, breast, muscle, connective tissue, lung
5 (including small-cell lung carcinoma and non-small-cell lung carcinoma), adrenal gland, thyroid,
6 kidney, or bone; or is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma,
7 sarcoma (including Kaposi's sarcoma), choriocarcinoma, cutaneous basocellular carcinoma, or
8 testicular seminoma.

1 **70.** The method of claim **68**, wherein the cancer is selected from the group
2 consisting of melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung
3 cancer, leukemia, a brain tumor, lymphoma, ovarian cancer, and Kaposi's sarcoma.

1 **71.** The method of claim **66**, wherein the disease, disorder, or condition is an
2 immune-related disease, disorder or condition selected from the group consisting of rheumatoid
3 arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, anemia
4 fibromyalgia, Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis,
5 arteriosclerosis, osteoporosis, Parkinson's disease, infections, Crohn's disease, ulcerative colitis,
6 allergic contact dermatitis and other eczemas, systemic sclerosis and multiple sclerosis.

1 **72.** A combination comprising a crystalline form of the compound of any one
2 of claims **1** to **64**, and at least one additional therapeutic agent.

1 **73.** The combination of claim **72**, wherein the at least one additional
2 therapeutic agent is a chemotherapeutic agent, an immune- and/or inflammation-modulating
3 agent, an anti-hypercholesterolemia agent, an anti-infective agent, or radiation.

1 **74.** The combination of claim **72**, wherein the at least one additional
2 therapeutic agent is an immune checkpoint inhibitor.

1 **75.** The combination of claim **74**, wherein the immune checkpoint inhibitor
2 selected from the group consisting of PD-1, PD-L1, BTLA, LAG-3, a B7 family member, TIM-
3 3, TIGIT and CTLA-4.

1 **76.** The combination of claim **73**, wherein the at least one additional
2 therapeutic agent is a chemotherapeutic agent selected from the group consisting of gemcitabine,
3 nab-paclitaxel, enzalutamide, doxorubicin, or any combinations thereof.

1 **77.** The combination of claim **73**, wherein the at least one additional
2 therapeutic agent is an immune-modulating agent that modulates the level of adenosine or
3 arginase.

1 **78.** A method of treating cancer in a subject, said method comprising
2 administering to said subject an effective amount of a crystalline form of the compound of any
3 one of claims **1** to **64**, and at least one additional therapeutic agent.

1 **79.** The method in accordance with claim **78**, wherein the at least one
2 additional therapeutic agent is a chemotherapeutic agent, an immune- and/or inflammation-
3 modulating agent, an anti-hypercholesterolemia agent, an anti-infective agent, or radiation.

1 **80.** The method in accordance with claim **78**, wherein the at least one
2 additional therapeutic agent is an immune checkpoint inhibitor.

1 **81.** The method in accordance with claim **80**, wherein the at least one
2 additional therapeutic agent is an immune checkpoint inhibitor selected from the group
3 consisting of PD-1, PD-L1, BTLA, LAG-3, a B7 family member, TIM-3, TIGIT and CTLA-4.

1 **82.** The method in accordance with claim **79**, wherein the at least one
2 additional therapeutic agent is a chemotherapeutic agent selected from the group consisting of
3 cisplatin, carboplatin, oxaliplatin, enzalutamide, docetaxel, nab-paclitaxel, gemcitabine, and
4 doxorubicin.

1 **83.** The method in accordance with claim **79**, wherein the at least one
2 additional therapeutic agent is an immune-modulating agent that modulates the level of
3 adenosine or arginase.

1 **84.** The method in accordance with claim **78**, wherein said compound and said
2 at least one additional therapeutic agent are administered in combination.

1 **85.** The method in accordance with claim **78**, wherein said compound and said
2 at least one additional therapeutic agent are administered sequentially.

1 **86.** The method in accordance with claim **85**, wherein said compound is
2 administered after said at least one additional therapeutic agent.

1 **87.** The method in accordance with claim **85**, wherein said compound is
2 administered prior to said at least one additional therapeutic agent.

1 **88.** The method in accordance with claim **78**, wherein treatment periods for
2 said compound and said at least one additional therapeutic agent overlap.

- 1 **89.** The method of claim **80**, wherein said immune checkpoint inhibitor is
2 zimberelimab or domvanalimab.